Effects of neurotoxic destruction of descending noradrenergic pathways on cannabinoid antinociception in models of acute and tonic nociception

Brain Research

Volumn 987, Issue 2, 2003, Pages 176-185

  Gutierrez, T ^a   Nackley, A G ^a   Neely, M H ^a   Freeman, K G ^b   Edwards, G L ^b   Hohmann, A G ^a  

^a University of Georgia ^*  (United States)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

Anandamide; Formalin test; Fos; Nociception

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID; DOPAMINE; FORMALDEHYDE; MONOAMINE; NORADRENALIN; OXIDOPAMINE; PROTEIN FOS; SEROTONIN; WIN 55 212 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; DRUG EFFECT; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; LUMBAR SPINAL CORD; MALE; NEUROTOXICITY; NOCICEPTION; NONHUMAN; NORADRENERGIC SYSTEM; PAIN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPINAL CORD DORSAL HORN; TAIL FLICK TEST;

EID: 0142134109     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(03)03324-9     Document Type: Article

References (52)

1. Abbott F.V., Franklin K.B., Westbrook R.F. The formalin test: scoring properties of the first and second phases of the pain response in rats. Pain. 60:1995;91-102.
2. Abbott F.V., Hong Y., Franklin K.B. The effect of lesions of the dorsolateral funiculus on formalin pain and morphine analgesia: a dose-response analysis. Pain. 65:1996;17-23.
3. Archer T., Jonsson G., Minor B.G., Post C. Noradrenergic-serotonergic interactions and nociception in the rat. Eur. J. Pharmacol. 120:1986;295-307.
4. Bullitt E. Expression of c-fos-like protein as a marker for neuronal activity following noxious stimulation in the rat. J. Comp. Neurol. 296:1990;517-530.
5. Clark F.M., Proudfit H.K. The projections of noradrenergic neurons in the A5 catecholamine cell group to the spinal cord in the rat: anatomical evidence that A5 neurons modulate nociception. Brain Res. 616:1993;200-210.
6. Coderre T.J., Fundytus M.E., McKenna J.E., Dalal S., Melzack R. The formalin test: a validation of the weighted-scores method of behavioural pain rating. Pain. 54:1993;43-50.
7. D'Amour F.E., Smith D.L. A method for determining the loss of pain sensation. J. Pharmacol. Exp. Ther. 72:1941;74-79.
8. Dubuisson D., Dennis S.G. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain. 4:1977;161-174.
9. Fasmer O.B., Berge O.G., Tveiten L., Hole K. Changes in nociception after 6-hydroxydopamine lesions of descending catecholaminergic pathways in mice. Pharmacol. Biochem. Behav. 24:1986;1441-1444.
10. Feria M., Sanchez A., Abad F., Abreu P. Effects of selective neurotoxic lesion of lumbosacral serotonergic and noradrenergic systems on autotomy behaviour in rats. Pain. 51:1992;101-109.
11. Fields H.L., Basbaum A.I. Central nervous system mechanism of pain modulation. Wall P.D., Melzack R. Textbook of Pain. 1999;309-329 Harcourt, London.
12. Fox A., Kesingland A., Gentry C., McNair K., Patel S., Urban L., James I. The role of central and peripheral cannabinoid 1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain. 92:2001;91-100.
13. Fritschy J.M., Grzanna R. Selective effects of DSP-4 on locus coeruleus axons: are there pharmacologically different types of noradrenergic axons in the central nervous system? Prog. Brain Res. 88:1991;257-268.
14. Greenhouse S.W., Geisser S. On methods in the analysis of profile data. Psychometrika. 24:1959;95-112.
15. Hernandez A., Laurido C., Mondaca M., Pelissier T., Burgos H., Soto-Moyano R. Lesion of the bulbospinal noradrenergic pathways blocks desipramine-induced inhibition of the C-fiber evoked nociceptive reflex in rats. Neurosci. Lett. 302:2001;1-4.
16. Hohmann A.G., Tsou K., Walker J.M. Cannabinoid modulation of wide dynamic range neurons in the lumbar dorsal horn of the rat by spinally administered WIN55,212-2. Neurosci. Lett. 257:1998;119-122.
17. Hohmann A.G., Tsou K., Walker J.M. Cannabinoid suppression of noxious heat-evoked activity in wide dynamic range neurons in the lumbar dorsal horn of the rat. J. Neurophysiol. 81:1999;575-583.
18. Hohmann A.G., Tsou K., Walker J.M. Intrathecal cannabinoid administration suppresses noxious stimulus-evoked Fos protein-like immunoreactivity in rat spinal cord: comparison with morphine. Zhongguo Yao Li Xue Bao. 20:1999;1132-1136.
19. Howe J.R., Yaksh T.L. Changes in sensitivity to intrathecal norepinephrine and serotonin after 6-hydroxydopamine (6-OHDA), 5,6-dihydroxytryptamine (5,6-DHT) or repeated monoamine administration. J. Pharmacol. Exp. Ther. 220:1982;311-321.
20. Hsu S.M., Raine L., Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem. Cytochem. 29:1981;577-580.
21. Hunt S.P., Pini A., Evan G. Induction of c-fos-like protein in spinal cord neurons following sensory stimulation. Nature. 328:1987;632-634.
22. Janss A.J., Jones S.L., Gebhart G.F. Effect of spinal norepinephrine depletion on descending inhibition of the tail flick reflex from the locus coeruleus and lateral reticular nucleus in the rat. Brain Res. 400:1987;40-52.
23. Jasmin L., Gogas K.R., Ahlgren S.C., Levine J.D., Basbaum A.I. Walking evokes a distinctive pattern of Fos-like immunoreactivity in the caudal brainstem and spinal cord of the rat. Neuroscience. 58:1994;275-286.
24. Kaneko M., Hammond D.L. Role of spinal gamma-aminobutyric acid A receptors in formalin-induced nociception in the rat. J. Pharmacol. Exp. Ther. 282:1997;928-938.
25. Kwiat G.C., Basbaum A.I. The origin of brainstem noradrenergic and serotonergic projections to the spinal cord dorsal horn in the rat. Somatosens. Motor Res. 9:1992;157-173.
26. Lichtman A.H., Martin B.R. Cannabinoid-induced antinociception is mediated by a spinal alpha 2-noradrenergic mechanism. Brain Res. 559:1991;309-314.
27. Lichtman A.H., Martin B.R. Spinal and supraspinal components of cannabinoid-induced antinociception. J. Pharmacol. Exp. Ther. 258:1991;517-523.
28. Lyons W.E., Fritschy J.M., Grzanna R. The noradrenergic neurotoxin DSP-4 eliminates the coeruleospinal projection but spares projections of the A5 and A7 groups to the ventral horn of the rat spinal cord. J. Neurosci. 9:1989;1481-1489.
29. Malmberg A.B., Yaksh T.L. Antinociceptive actions of spinal non-steroidal anti-inflammatory agents on the formalin test in the rat. J. Pharmacol. Exp. Ther. 263:1992;136-146.
30. Martin B.R., Compton D.R., Thomas B.F., Prescott W.R., Little P.J., Razdan R.K., Johnson M.R., Melvin L.S., Mechoulam R., Ward S.J. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol. Biochem. Behav. 40:1991;471-478.
31. Martin W.J., Hohmann A.G., Walker J.M. Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects. J. Neurosci. 16:1996;6601-6611.
32. Martin W.J., Tsou K., Walker J.M. Cannabinoid receptor-mediated inhibition of the rat tail-flick reflex after microinjection into the rostral ventromedial medulla. Neurosci. Lett. 242:1998;33-36.
33. Martin W.J., Loo C.M., Basbaum A.I. Spinal cannabinoids are anti-allodynic in rats with persistent inflammation. Pain. 82:1999;199-205.
34. Martin W.J., Coffin P.O., Attias E., Balinsky M., Tsou K., Walker J.M. Anatomical basis for cannabinoid-induced antinociception as revealed by intracerebral microinjections. Brain Res. 822:1999;237-242.
35. Martin W.J., Gupta N.K., Loo C.M., Rohde D.S., Basbaum A.I. Differential effects of neurotoxic destruction of descending noradrenergic pathways on acute and persistent nociceptive processing. Pain. 80:1999;57-65.
36. Meng I.D., Manning B.H., Martin W.J., Fields H.L. An analgesia circuit activated by cannabinoids. Nature. 395:1998;381-383.
37. Monhemius R., Azami J., Green D.L., Roberts M.H. CB1 receptor mediated analgesia from the nucleus reticularis gigantocellularis pars alpha is activated in an animal model of neuropathic pain. Brain Res. 908:2001;67-74.
38. Nackley A.G., Makriyannis A., Hohmann A.G. Selective activation of cannabinnoid CB2 receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience. 119:2003;747-757.
39. Nackley A.G., Suplita II R.L., Hohmann A.G. A peripheral cannabinoid mechanism suppresses spinal Fos protein expression and pain behavior in a rat model of inflammation. Neuroscience. 117:2003;659-670.
40. Naranjo J.R., Arnedo A., Molinero M.T., Del Rio J. Involvement of spinal monoaminergic pathways in antinociception produced by substance P and neurotensin in rodents. Neuropharmacology. 28:1989;291-298.
41. Post C., Persson M.L., Archer T., Minor B.G., Danysz W., Sundstrom E. Increased antinociception by alpha-adrenoceptor drugs after spinal cord noradrenaline depletion. Eur. J. Pharmacol. 137:1987;107-116.
42. Presley R.W., Menetrey D., Levine J.D., Basbaum A.I. Systemic morphine suppresses noxious stimulus-evoked Fos protein-like immunoreactivity in the rat spinal cord. J. Neurosci. 10:1990;323-335.
43. Sawynok J., Reid A.R., Doak G.J. Caffeine antinociception in the rat hot-plate and formalin tests and locomotor stimulation: involvement of noradrenergic mechanisms. Pain. 61:1995;203-213.
44. Smith P.B., Martin B.R. Spinal mechanisms of delta 9-tetrahydrocannabinol-induced analgesia. Brain Res. 578:1992;8-12.
45. Soares J., Holmes P.V., Renner K.J., Edwards G.L., Bunnell B.N., Dishman R.K. Brain noradrenergic responses to footshock after chronic activity-wheel running. Behav. Neurosci. 113:1999;558-566.
46. Tjolsen A., Berge O.G., Hole K. Lesions of bulbo-spinal serotonergic or noradrenergic pathways reduce nociception as measured by the formalin test. Acta Physiol. Scand. 142:1991;229-236.
47. Tsou K., Lowitz K.A., Hohmann A.G., Martin W.J., Hathaway C.B., Bereiter D.A., Walker J.M. Suppression of noxious stimulus-evoked expression of Fos protein-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist. Neuroscience. 70:1996;791-798.
48. Walker J.M., Huang S.M., Strangman N.M., Tsou K., Sanudo-Pena M.C. Pain modulation by release of the endogenous cannabinoid anandamide. Proc. Natl. Acad. Sci. USA. 96:1999;12198-12203.
49. Welch S.P., Thomas C., Patrick G.S. Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine. J. Pharmacol. Exp. Ther. 272:1995;310-321.
50. Yaksh T.L., Rudy T.A. Chronic catheterization of the spinal subarachnoid space. Physiol. Behav. 17:1976;1031-1036.
51. Yamazaki N., Umeno H., Kuraishi Y. Involvement of brain serotonergic terminals in the antinociceptive action of peripherally applied calcitonin. Jpn. J. Pharmacol. 81:1999;367-374.
52. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain. 16:1983;109-110.